Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

NIH Executive Fired Amid Contract Probe Involving Spouse

The National Institutes of Health (NIH) has terminated the employment of its chief operating officer, Eric Schnabel, following allegations of potential misconduct related to a $3.3 million contract award. The dismissal comes amid an ongoing investigation into whether Schnabel's wife could have benefited from the agreement, according to a report by The Washington Post.

NoahAI News7/17/2025

FDA Lifts Partial Hold on Kezar's Zetomipzomib Trial for Autoimmune Hepatitis

The U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on Kezar Life Sciences' phase 2a Portola trial, evaluating the selective immunoproteasome inhibitor zetomipzomib in patients with autoimmune hepatitis (AIH). This development marks a significant step forward for Kezar's AIH program and potentially opens the door for further clinical advancements.

NoahAI News7/17/2025

Amphastar Pharmaceuticals Unveils Ambitious Expansion Plan to Boost Domestic Manufacturing

Amphastar Pharmaceuticals, a long-standing player in the generics market, has announced a bold initiative to significantly expand its manufacturing capabilities at its headquarters in Rancho Cucamonga, California. The company plans to quadruple its production capacity over the next three to five years, marking its largest-ever investment in infrastructure.

NoahAI News7/17/2025

ChristianaCare and Virtua Health Explore $6.3B Merger to Form Regional Healthcare Powerhouse

In a significant development for the healthcare landscape of the Mid-Atlantic region, ChristianaCare and Virtua Health have announced plans to explore a potential $6.3 billion merger. The proposed combination would create an expansive nonprofit regional health system spanning four states and encompassing eight hospitals.

NoahAI News7/17/2025

Sarepta Therapeutics Announces Major Restructuring and Pipeline Shift Amid Safety Concerns

Sarepta Therapeutics, a leading gene therapy company, has unveiled a significant restructuring plan that includes substantial layoffs and a strategic pivot in its research focus. This move comes as the company grapples with safety concerns surrounding its flagship product, Elevidys, for Duchenne muscular dystrophy (DMD).

NoahAI News7/17/2025

AstraZeneca's AL Amyloidosis Drug Fails to Meet Primary Endpoint in Phase 3 Trial

AstraZeneca's hopes for a potential blockbuster drug in the rare disease space have been dealt a significant blow as its light chain (AL) amyloidosis candidate, anselamimab, failed to meet its primary endpoint in a pivotal phase 3 trial. The study, which involved 406 patients across 19 countries, did not demonstrate a statistically significant reduction in all-cause mortality or frequency of cardiovascular hospitalizations.

NoahAI News7/17/2025

Real Chemistry Announces Leadership Changes to Drive Growth and Innovation

Real Chemistry, a prominent healthcare marketing and communications group, has unveiled a series of strategic leadership appointments aimed at bolstering its position in the competitive pharmaceutical industry landscape. The company's latest moves demonstrate a commitment to enhancing its client partnerships and driving meaningful impact across its various divisions.

NoahAI News7/17/2025

FDA Raises Concerns Over Rexulti-Zoloft Combination for PTSD Treatment

The U.S. Food and Drug Administration (FDA) has expressed reservations about the efficacy of a proposed combination therapy for post-traumatic stress disorder (PTSD), developed by Lundbeck and Otsuka Pharmaceutical. The treatment, which combines Rexulti (brexpiprazole) with Viatris' Zoloft (sertraline), is currently under review by the agency's Psychopharmacologic Drugs Advisory Committee.

NoahAI News7/17/2025

Otsuka Pharmaceutical Expands Autoimmune Pipeline with $613M Cantargia Deal

Otsuka Pharmaceutical has taken a significant step to bolster its presence in the autoimmune and inflammatory disease space, signing a $613 million deal with Swedish biotech Cantargia for its IL1RAP antibody program. The agreement, announced on July 15, 2025, marks Otsuka's latest move to strengthen its R&D pipeline in autoimmune conditions.

NoahAI News7/17/2025

OpenEvidence Secures $210M in Series B Funding, Unveils Advanced AI for Medical Research

OpenEvidence, a rapidly growing artificial intelligence startup in the medical field, has successfully raised $210 million in a Series B funding round, propelling its valuation to $3.5 billion. The company, which has developed an AI-powered medical search engine and generative AI chatbot for doctors, plans to use the funds to expand its strategic content partnerships and enhance its advanced medical knowledge library.

NoahAI News7/16/2025

Repare Therapeutics Offloads PKMYT1 Inhibitor to Debiopharm in Strategic Deal

Repare Therapeutics has found a new home for its paused PKMYT1 inhibitor, lunresertib, in a deal with Swiss pharmaceutical company Debiopharm. The agreement, announced on July 15, 2025, marks a significant development in Repare's ongoing strategy to streamline its pipeline and focus on key clinical priorities.

NoahAI News7/16/2025

Audrey Greenberg: Pioneering a New Era in Pharmaceutical Innovation

In a career marked by pivotal moments and strategic decisions, Audrey Greenberg has emerged as a transformative figure in the pharmaceutical industry. From her early days on Wall Street to her recent appointment as a partner at Mayo Clinic's new venture arm, Greenberg's journey exemplifies the power of adaptability and vision in shaping the future of healthcare.

NoahAI News7/16/2025

«1...14 15 16...67 »